DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 151,500 shares, a decline of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the days-to-cover ratio is currently 1.8 days.

DiaMedica Therapeutics Trading Down 2.1 %

NASDAQ DMAC traded down $0.11 on Tuesday, hitting $5.20. The company’s stock had a trading volume of 66,743 shares, compared to its average volume of 58,844. The firm has a market cap of $222.36 million, a P/E ratio of -9.48 and a beta of 1.51. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $5.74. The company’s 50-day simple moving average is $4.64 and its 200 day simple moving average is $3.88.

Institutional Trading of DiaMedica Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in DiaMedica Therapeutics in the third quarter worth about $40,000. Magnolia Capital Advisors LLC purchased a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at approximately $87,000. Blue Trust Inc. bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $185,000. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after buying an additional 211,351 shares during the period. Hedge funds and other institutional investors own 10.12% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.